SWOG clinical trial number
CTSU/NRG-GY018

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Open
Phase
Abbreviated Title
Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Research committees

Early Therapeutics & Rare Cancers

Other Clinical Trials

CTSU/AOST2032
SWOG Clinical Trial Number

AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
CTSU/AOST2031
SWOG Clinical Trial Number

AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open
S2012
SWOG Clinical Trial Number

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12/02/2021
51% Accrual
Accrual
51%
Open
Phase